QUEST DIAGNOSTICS INCORPORATED Quest Diagnostics Incorporated Share Price
Equities
DGX
US74834L1008
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 134.3 USD | -0.86% |
|
+4.53% | -2.63% |
| 04-25 | Labcorp beats quarterly estimates on strong testing demand | RE |
| 04-24 | Jefferies Adjusts Price Target on Quest Diagnostics to $160 From $155 | MT |
| Sales 2024 * | 9.45B 756B | Sales 2025 * | 9.75B 780B | Capitalization | 14.92B 1,194B |
|---|---|---|---|---|---|
| Net income 2024 * | 894M 71.57B | Net income 2025 * | 960M 76.85B | EV / Sales 2024 * | 2.01 x |
| Net Debt 2024 * | 4.07B 326B | Net Debt 2025 * | 3.44B 275B | EV / Sales 2025 * | 1.88 x |
| P/E ratio 2024 * |
17.2
x | P/E ratio 2025 * |
15.8
x | Employees | 44,000 |
| Yield 2024 * |
2.15% | Yield 2025 * |
2.22% | Free-Float | 68.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on Quest Diagnostics Incorporated
More recommendations
More press releases
More news
| 1 day | -0.86% | ||
| 1 week | +4.53% | ||
| Current month | +0.86% | ||
| 1 month | +4.18% | ||
| 3 months | +2.93% | ||
| 6 months | +2.29% | ||
| Current year | -2.63% |
1 week
128.38
138.91
1 month
125.42138.91
Current year
123.04143.63
1 year
119.59145.58
3 years
119.59174.16
5 years
73.02174.16
10 years
54.90174.16
| Managers | Title | Age | Since |
|---|---|---|---|
James Davis
CEO | Chief Executive Officer | 61 | 31/03/13 |
Sam Samad
DFI | Director of Finance/CFO | 54 | 10/07/22 |
Kristin Wallace
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Denise Morrison
BRD | Director/Board Member | 70 | 17/02/19 |
Timothy Ring
BRD | Director/Board Member | 66 | 06/12/11 |
Gail Wilensky
BRD | Director/Board Member | 80 | 31/12/96 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.84% | 215 M€ | +10.68% | - | |
| 2.17% | 2 M€ | +6.77% | ||
| 2.05% | 8 M€ | +2.44% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 134.3 | -0.86% | 601,735 |
| 25/04/24 | 135.4 | -1.55% | 1,016,098 |
| 24/04/24 | 137.6 | +0.62% | 1,566,638 |
| 23/04/24 | 136.7 | +5.08% | 2,088,321 |
| 22/04/24 | 130.1 | +1.28% | 1,694,278 |
Delayed Quote Nyse, April 26, 2024 at 09:00 pm
More quotes
Quest Diagnostics is the world's leading provider of diagnostics testing and information service for patients and health professionals. Net sales break down by activity as follows:
- testing and diagnostic services (97.3%): routine clinical testing, gene-based testing and advanced diagnostic and anatomica pathology diagnostic services;
- other (2.7%).
Calendar
23/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
134.3
USD
Average target price
146
USD
Spread / Average Target
+8.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.63% | 14.92B | |
| -14.92% | 84.68B | |
| +13.30% | 81.12B | |
| +10.92% | 29.4B | |
| -12.71% | 16.73B | |
| -3.06% | 16.36B | |
| -3.97% | 11.66B | |
| -1.42% | 11.72B | |
| -31.75% | 11.77B | |
| +27.44% | 11.71B |
- Stock Market
- Equities
- DGX Stock
